Business Services

OncoSec

$7.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (+1.97%) Today
$0.00 (0.00%) As of 10:10 AM UTC after-hours

Why Robinhood?

You can buy or sell OncoSec and other stocks, options, and ETFs commission-free!

About ONCS

OncoSec Medical Incorporated Common Stock, also called OncoSec, is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered inPennington, NJ. The listed name for ONCS is OncoSec Medical Incorporated Common Stock.

CEO
Daniel J. O'Connor
Employees
46
Headquarters
Pennington, New Jersey
Founded
2008
Market Cap
164.41M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
579.07K
High Today
$7.43
Low Today
$6.55
Open Price
$6.96
Volume
518.97K
52 Week High
$7.43
52 Week Low
$1.04

Collections

ONCS Earnings

-$1.27
-$0.85
-$0.42
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Mar 12, After Hours

You May Also Like

MEIP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure